SAN DIEGO, Feb. 5, 2020 /PRNewswire/ -- DelMar
Pharmaceuticals, Inc. (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical
company focused on the development of new solid tumor cancer
therapies, today announced that Mr. Saiid
Zarrabian, Chief Executive Officer of DelMar will attend the 22nd Annual BIO CEO
& Investor Conference being held on February 10 and 11, 2020, at the New York
Marriott Marquis in New York City.
Mr. Zarrabian will be available for one-on-one meetings during the
two-day event.
Investors or others interested in meeting with management are
encouraged to request a meeting through the conference's one-on-one
meetings system.
About the BIO CEO & Investor Conference
The BIO CEO & Investor Conference is one of the largest
investor conferences focused on established and emerging publicly
traded and select private biotech companies. Each year, the BIO CEO
& Investor Conference provides a forum where institutional
investors, industry analysts, and senior biotechnology executives
have the opportunity to meet.
About DelMar Pharmaceuticals, Inc.
Located in San Diego,
California, DelMar is
focused on the development and commercialization of new therapies
for cancer patients who have limited or no treatment options. By
focusing on understanding tumor biology and mechanisms of treatment
resistance, the Company identifies biomarkers to personalize new
therapies in indications where patients are failing, or are unable
to tolerate, standard-of-care treatments.
The Company's current pipeline is based around VAL-083, a
"first-in-class", small-molecule chemotherapeutic with a novel
mechanism of action that has demonstrated clinical activity against
a range of cancers, including central nervous system, ovarian and
other solid tumors (e.g. NSCLC, bladder cancer, head & neck) in
U.S. clinical trials sponsored by the National Cancer Institute
(NCI). Based on DelMar's internal
research programs and these prior NCI-sponsored clinical studies,
the Company is conducting clinical trials to support the
development and commercialization of VAL-083 to solve significant
unmet medical needs.
VAL-083 is being studied in two collaborator-supported,
biomarker-driven Phase 2 clinical trials for MGMT-unmethylated GBM.
Overcoming MGMT-mediated resistance represents a significant unmet
medical need in the treatment of GBM. In addition, DelMar has announced the allowance of a
separate IND for VAL-083 as a potential treatment for
platinum-resistant ovarian cancer.
Further information on DelMar's
clinical trials can be found on clinicaltrials.gov:
https://www.clinicaltrials.gov/ct2/results?cond=&term=val-083&cntry1=&state1=&recrs.
For additional information, please visit http://delmarpharma.com/;
or contact DelMar Pharmaceuticals Investor Relations:
ir@delmarpharma.com / (604) 629-5989.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995, including statements regarding the status of the
Company's clinical trials and the reporting of the
results. Any forward-looking statements contained herein are
based on current expectations but are subject to a number of risks
and uncertainties. The factors that could cause actual future
results to differ materially from current expectations include, but
are not limited to, risks and uncertainties relating to the
Company's ability to develop, market and sell products based on its
technology; the expected benefits and efficacy of the Company's
products and technology; the availability of substantial additional
funding for the Company to continue its operations and to conduct
research and development, clinical studies and future product
commercialization; and, the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies. These and other factors are identified and
described in more detail in the Company's filings with the SEC,
including the Company's Annual Report on Form 10-K for the year
ended June 30, 2019, the Company's
Quarterly Reports on Form 10-Q, and the Company's Current Reports
on Form 8-K.
CONTACTS:
Investors:
John
Marco
Managing Director
CORE IR
516-222-2560
johnm@coreir.com
Media:
Jules
Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-attend-the-22nd-annual-bio-ceo--investor-conference-in-new-york-city-february-10-and-11-2020-300999030.html
SOURCE DelMar Pharmaceuticals, Inc.